Generic PHENTERMINE RESIN COMPLEX INN equivalents, drug patent expiry and freedom to operate

Sponsor	Phase
Russell McCulloh, MD	PHASE2
National Institutes of Health (NIH)	PHASE2
IDeA States Pediatric Clinical Trials Network	PHASE2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Quantum Pharmics	PHENTERMINE RESIN 30	phentermine resin complex	CAPSULE, EXTENDED RELEASE;ORAL	089120-001	Feb 4, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lannett Co Inc	PHENTERMINE RESIN COMPLEX	phentermine resin complex	CAPSULE, EXTENDED RELEASE;ORAL	040872-002	Jul 28, 2011		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ucb Inc	IONAMIN	phentermine resin complex	CAPSULE, EXTENDED RELEASE;ORAL	011613-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 3, 2026

Phentermine resin complex is a mature, low-cost prescription appetite suppressant with limited patent protection, generic competition, and no meaningful biologic or formulation exclusivity. Its commercial value comes from established prescribing patterns, low acquisition cost, and controlled-substance demand rather than from proprietary intellectual property. The product remains exposed to competition from phentermine hydrochloride tablets and capsules, combination products such as phentermine/topiramate, and newer anti-obesity therapies, including GLP-1 receptor agonists.

What is phentermine resin complex?

Phentermine resin complex is an extended-release formulation of phentermine, a sympathomimetic amine used as a short-term adjunct to caloric restriction and behavioral modification for weight reduction. The resin complex controls release of the active drug compared with immediate-release phentermine products.

The principal branded product associated with the ingredient is Ionamin. Generic products are marketed under descriptions such as "phentermine resin complex capsules." The product is not a biologic and does not require biosimilar competition. It is regulated as a Schedule IV controlled substance in the United States because of its stimulant and abuse-potential profile.[1][2]

Key product characteristics

Attribute	Phentermine resin complex
Active ingredient	Phentermine bound to an ion-exchange resin
Primary use	Short-term obesity treatment
Drug class	Sympathomimetic anorectic
Typical dosage form	Extended-release oral capsule
U.S. regulatory status	Prescription drug
Controlled-substance status	Schedule IV
Reference brand	Ionamin
Main competitors	Phentermine hydrochloride, phentermine/topiramate, GLP-1 therapies
Patent position	Mature and generally non-proprietary
Biosimilar exposure	None

The FDA label limits use to short-term therapy. The label also identifies contraindications including cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, a history of drug abuse, and use with monoamine oxidase inhibitors.[1]

How large is the phentermine resin complex market?

The product-specific market is small relative to the broader U.S. anti-obesity market, and publicly reported financial data do not isolate phentermine resin complex sales. Manufacturers that sell generic capsules generally report revenue at a portfolio or segment level rather than by active ingredient.

The broader phentermine market is materially larger than the resin-complex segment because immediate-release phentermine tablets and capsules are widely prescribed and available from multiple manufacturers. Phentermine remains one of the lowest-cost pharmacologic options for obesity treatment, which supports continued demand among cash-pay patients and patients whose insurance does not cover anti-obesity medicines.

Market drivers

Demand is supported by four factors:

Low generic pricing compared with branded or newer anti-obesity therapies.
Broad prescriber familiarity with phentermine.
Availability through retail pharmacies, weight-management clinics, and telehealth providers.
Continued obesity prevalence and patient demand for pharmacologic weight loss.

The commercial limitations are equally clear. Phentermine resin complex is approved for short-term use, while many newer therapies are positioned for chronic weight management. The product also lacks the cardiovascular and metabolic outcome profile increasingly demanded by payers and prescribers.

How does phentermine resin complex compare with newer obesity drugs?

Phentermine resin complex competes primarily on price and access. Newer medicines compete on efficacy, duration of therapy, metabolic benefits, and clinical-trial evidence.

Product category	Active ingredient or class	Treatment duration	Relative cost	Commercial position
Phentermine resin complex	Phentermine extended release	Short term	Low	Generic, price-driven
Phentermine immediate release	Phentermine hydrochloride	Short term	Low	Larger and more liquid generic market
Qsymia	Phentermine/topiramate extended release	Chronic treatment	High	Branded combination product
Wegovy	Semaglutide	Chronic treatment	Very high	GLP-1 obesity franchise
Zepbound	Tirzepatide	Chronic treatment	Very high	Dual GIP/GLP-1 franchise
Contrave	Naltrexone/bupropion	Chronic treatment	Moderate to high	Branded oral alternative

Phentermine resin complex does not directly replicate the efficacy or treatment model of semaglutide or tirzepatide. It is more likely to retain a low-price, short-duration role than to compete for premium reimbursement.

What is the financial trajectory of the product?

The likely financial trajectory is mature-to-declining revenue, with periodic volume support from obesity-treatment demand and cash-pay channels. Unit demand can remain stable even while industry revenue declines because generic price erosion reduces sales value.

The most relevant financial variables are:

Prescription volume rather than price expansion.
Generic supplier count.
Retail acquisition cost.
Controlled-substance distribution restrictions.
Manufacturing continuity.
Demand migration to GLP-1 therapies.
Reimbursement coverage for branded obesity drugs.
Telehealth and clinic dispensing practices.

A product-level revenue forecast cannot be derived from public issuer filings because companies generally do not disclose sales for phentermine resin complex separately. The absence of product-level disclosure is consistent with a mature generic product that is not financially material to diversified manufacturers.

Revenue exposure by business model

Business model	Revenue exposure
Originator brand	Limited, unless the brand retains a differentiated distribution position
Generic manufacturer	Low-margin, volume-dependent revenue
Contract manufacturer	Stable production opportunity, subject to price competition
Distributor	High unit turnover but limited product-specific margin visibility
Weight-management clinic	Potentially attractive cash-pay economics, subject to state and federal rules
Telehealth provider	Demand-generation opportunity, with controlled-substance compliance risk
Large GLP-1 manufacturer	Minimal direct exposure; phentermine is primarily a lower-cost substitute

What patents protect phentermine resin complex?

The core product is not protected by a commercially significant unexpired U.S. patent estate. The original formulation and product claims date from the early development period of phentermine products, and the relevant exclusivity periods have expired.

The principal intellectual-property categories historically associated with the product are:

The phentermine active compound.
Resin-complexation technology.
Extended-release capsule formulations.
Manufacturing methods for binding phentermine to an ion-exchange resin.
Dosing and administration methods.

These rights are old relative to the current generic market. Any remaining patent risk would more likely involve a specific manufacturer’s process, packaging, or formulation improvement than the basic phentermine resin complex itself.

How strong is the patent estate?

Patent factor	Assessment
Core compound patent	Expired
Original resin-complex formulation	Expired or commercially ineffective
Orange Book exclusivity	No meaningful current barrier identified
Formulation patent risk	Low for the established product
Manufacturing patent risk	Potentially relevant only to a particular process
Paragraph IV leverage	Limited
Generic entry barrier	Primarily regulatory and commercial, not patent-based

The FDA Orange Book remains the controlling source for current patent and exclusivity listings. Product-specific review should distinguish phentermine resin complex from newer combination products, particularly Qsymia, whose patent estate is materially different.[3][4]

When does phentermine resin complex lose exclusivity?

The product has already lost the exclusivity associated with its original approval. Generic competition is established, and market access is not dependent on a future loss-of-exclusivity event.

The relevant timeline is:

Period	Commercial event
Original development era	Phentermine resin-complex technology introduced
Initial approval period	Branded Ionamin-style products commercialized
Generic-entry period	ANDA competition established
Post-exclusivity period	Price competition and portfolio marketing became dominant
Current market	Mature generic product with no major patent cliff

The key business question is therefore not when exclusivity ends. It is whether a manufacturer can maintain supply, obtain favorable wholesaler terms, and preserve sufficient margin in a crowded generic market.

Which companies are challenging the product?

Generic competition is dispersed across manufacturers and private-label suppliers. The most commercially relevant competitors are companies with established generic controlled-substance manufacturing and distribution capabilities, rather than companies pursuing a single high-value Paragraph IV challenge.

The competitive set can include:

Generic capsule manufacturers.
Authorized distributors and pharmacy suppliers.
Weight-management clinics.
Telehealth operators.
Manufacturers of immediate-release phentermine.
Branded suppliers of phentermine/topiramate.

Because phentermine resin complex is an established generic product, litigation is more likely to involve manufacturing, supply, controlled-substance distribution, labeling, or commercial practices than a major patent dispute over the active ingredient.

What is the FDA regulatory status?

Phentermine resin complex is an FDA-approved prescription product when marketed under an approved application or abbreviated new drug application. Approval does not authorize unrestricted long-term obesity treatment. The FDA labeling framework describes phentermine as a short-term adjunct to diet and exercise.[1]

Regulatory issues affecting market value

The principal regulatory risks are:

Schedule IV controlled-substance compliance.
Prescribing outside labeled duration.
Combination with other weight-loss drugs without adequate clinical justification.
Cardiovascular and psychiatric adverse events.
Distribution through online pharmacies and telehealth channels.
State-level prescribing and dispensing requirements.
Product-quality and supply-chain controls.
Advertising claims that imply chronic use or superior efficacy.

The FDA has also maintained a strict distinction between approved phentermine products and compounded or unapproved weight-loss products. Manufacturers and providers that rely on compounded formulations face a different regulatory risk profile from approved resin-complex capsules.[5]

Are there Paragraph IV challenges to phentermine resin complex?

Paragraph IV litigation is not a central current risk for the established resin-complex market. The product’s core exclusivity has expired, and generic products are already available. A new entrant would generally face ordinary ANDA, manufacturing, bioequivalence, and controlled-substance requirements rather than a high-value patent settlement process.

Any Paragraph IV certification would need to relate to a currently listed, unexpired patent covering the specific reference product. Historic patents associated with phentermine or early resin-complex technology would not ordinarily block current generic entry after expiration.

What formulation patents protect extended-release phentermine?

The commercial differentiation of the resin complex lies in controlled release. In practice, the formulation must demonstrate acceptable release characteristics, content uniformity, stability, and bioequivalence to the reference product.

Potential formulation barriers include:

Resin particle size and loading.
Drug-release kinetics.
Capsule composition.
Manufacturing conditions.
Stability and impurity controls.
Bioequivalence requirements for modified-release products.

These factors can delay approval or increase development costs, but they do not create the same barrier as an unexpired composition-of-matter patent. A manufacturer may have proprietary know-how without possessing a market-blocking patent.

What manufacturing and IP barriers exist?

Manufacturing is the more relevant barrier than patent exclusion. Suppliers must manage:

Controlled-substance quotas and reporting.
Secure handling and inventory reconciliation.
Resin-drug binding consistency.
Modified-release performance.
Batch-to-batch uniformity.
FDA inspection readiness.
API sourcing and supplier qualification.
Product discontinuation risk from low margins.

The resin-complex process may require specialized equipment and analytical testing. Those requirements can reduce the number of credible suppliers, but they do not necessarily support premium pricing. If several manufacturers maintain approval and supply, buyers can substitute products readily.

What generic launch scenarios are possible?

Three scenarios define the commercial outlook.

Base case: stable low-cost demand

Phentermine remains widely prescribed because of its price and familiarity. Resin-complex volume stays stable, but net selling prices remain under pressure. Manufacturers preserve the product as part of a broader generic portfolio.

Downside case: substitution by GLP-1 therapies

Improved insurance access and sustained supply of semaglutide and tirzepatide shift patients toward chronic therapies. Resin-complex prescriptions decline, while price erosion accelerates. Smaller suppliers may discontinue the product.

Upside case: cash-pay obesity growth

High out-of-pocket prices for GLP-1 products drive patients toward lower-cost oral therapies. Phentermine demand increases through primary care, clinics, and telehealth. Regulatory scrutiny of prescribing practices limits the upside.

The upside case supports prescription volume but is unlikely to restore branded-style margins.

What litigation and settlement agreements affect the market?

No major current patent settlement is central to the mature phentermine resin-complex market. Commercial disputes are more likely to involve:

Product liability claims.
Controlled-substance distribution.
False or misleading weight-loss advertising.
Pharmacy and telehealth prescribing practices.
Manufacturing quality.
Contract supply and channel disputes.

The product carries known stimulant-related risks, including increased blood pressure, palpitations, insomnia, nervousness, and rare pulmonary hypertension or valvular disease concerns described in labeling.[1]

Key Takeaways

Phentermine resin complex is a mature extended-release phentermine product with no meaningful remaining core patent barrier.
Its market is generic, price-sensitive, and fragmented.
Product-specific revenue is not separately reported by major manufacturers.
Financial performance depends on prescription volume, supply continuity, and cash-pay obesity demand.
Immediate-release phentermine is the closest low-cost substitute.
GLP-1 therapies are the principal long-term competitive threat.
The major barriers are FDA compliance, controlled-substance controls, manufacturing consistency, and distribution economics.
Paragraph IV litigation and patent settlements are not central current risks.
The likely financial trajectory is stable or declining revenue with occasional volume growth and continuing price erosion.
The product retains commercial relevance because it is inexpensive, orally administered, widely recognized, and accessible outside premium obesity-drug reimbursement channels.

FAQs About Phentermine Resin Complex

Is phentermine resin complex the same as phentermine hydrochloride?

No. Both deliver phentermine, but phentermine resin complex is an extended-release formulation in which the drug is associated with a resin. Phentermine hydrochloride products are generally immediate-release tablets or capsules.

Is Ionamin still a protected brand?

The original Ionamin exclusivity has expired. Any current brand rights, trademarks, or commercial distribution rights are separate from patent protection and do not prevent generic competition.

Can phentermine resin complex be used for long-term weight loss?

The FDA labeling describes phentermine products as short-term adjuncts to diet and exercise. Long-term prescribing raises labeling, clinical, and regulatory considerations that differ from the approved short-term indication.[1]

Does phentermine resin complex have biosimilar competition?

No. Phentermine resin complex is a chemically synthesized small-molecule drug. Competition occurs through generic approval pathways, not biosimilar applications.

Why can the product remain profitable after patent expiry?

Low manufacturing costs, established demand, recurring prescriptions, and cash-pay access can support profitability. Margins are constrained by generic competition, controlled-substance compliance, and substitution by newer obesity therapies.

References

U.S. Food and Drug Administration. (n.d.). Phentermine hydrochloride and phentermine resin complex prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ fda-concerns-unapproved-glp-1-drugs-used-weight-loss

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	53
DailyMed Link:	PHENTERMINE RESIN COMPLEX at DailyMed

PHENTERMINE RESIN COMPLEX - Generic Drug Details

What are the generic sources for phentermine resin complex and what is the scope of freedom to operate?

Summary for PHENTERMINE RESIN COMPLEX

Recent Clinical Trials for PHENTERMINE RESIN COMPLEX

Anatomical Therapeutic Chemical (ATC) Classes for PHENTERMINE RESIN COMPLEX

US Patents and Regulatory Information for PHENTERMINE RESIN COMPLEX

Phentermine Resin Complex Market Dynamics and Financial Trajectory